We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

WATERS CORPORATION

Waters Corp. designs, manufactures, sells and services ultra performance liquid chromatography (UPLC), high performan... read more Featured Products: More products

Download Mobile App




UPLC-MS/MS Method Simultaneously Determines Plasma Catecholamines and Their Metabolites

By LabMedica International staff writers
Posted on 27 Jan 2021
Print article
Image: ACQUITY I-Class UPLC coupled with Xevo TQ-S mass spectrometer (Photo courtesy of Waters Corporation).
Image: ACQUITY I-Class UPLC coupled with Xevo TQ-S mass spectrometer (Photo courtesy of Waters Corporation).
Phaeochromocytomas and paragangliomas (PPGLs) are rare tumors of adrenal chromaffin cells or extra-adrenal paraganglia. They are difficult to diagnose because of the non-specific clinical symptoms such as hypertension, palpitations, flushing and sweating.

Inappropriate catecholamines (CAs) production was normally used for the diagnosis of PPGLs in the clinical laboratory. New guideline recommends screening of fractionated urinary metanephrines (MNs, the metabolites of CAs) or plasma free MNs using high performance liquid chromatography with electrochemical detection (HPLC-ECD) or liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) as MNs are continuously secreted by the tumor.

Laboratory Medical Scientists at the Sichuan Provincial People’s Hospital (Sichuan, China) and their colleagues collected plasma samples in EDTA anticoagulant tubes by venipuncture in a seated position from patients. Plasma samples were pretreated with solid-phase extraction, followed by a 3-minute UPLC-MS/MS analysis to quantify epinephrine (E), norepinephrine (NE), dopamine (DA), metanephrine (MN), normetanephrine (NMN) and 3-methoxytyramine (3-MT), simultaneously.

A Waters ACQUITY I-Class UPLC coupled with Xevo TQ-S mass spectrometer (Waters Corporation, Milford, MA, USA) was used for analysis. Chromatographic separation was carried out using an Agilent Pursuit 3 PFP column (150 × 2.0 mm, 3.0 μm) (Agilent Technologies, Santa Clara, CA, USA) kept at 40 °C during analysis. The UPLC-MS/MS method was comprehensively verified and its diagnostic efficiency on PPGLs was tested using seven PPGLs and 408 non-PPGLs patient plasma samples.

After the UPLC-MS/MS method was verified, the seven PPGLs and 408 non-PPGLs patient plasma samples were used to assess its diagnostic efficiency. The median concentrations of the six analytes in the PPGLs patients were determined to be: E, 0.36 nmol/L; NE, 8.47 nmol/L; DA, 0.09 nmol/L; MN, 0.26 nmol/L; NMN, 6.26 nmol/L; and 3-MT, 5.35 pg/mL. The results showed that the median concentration of E of PPGLs group was significantly higher than that of cerebral hemorrhage group, but showed no significant difference to the other six non-PPGLs groups. The median concentration of NE of PPGLs group was significantly higher than almost all the non-PPGLs groups, except for cardiac diseases group. The median concentration of NMN of PPGLs group was significant higher than all non-PPGLs groups.

The authors concluded their study presented a UPLC-MS/MS method with high sensitivity and selectivity, good extraction recoveries and low matrix interferences for determining the concentrations of catecholamines and metabolites in human plasma. ROC curve analysis showed that the developed method provided excellent diagnostic performance in patients tested for PPGLs, which was validated to be an effective tool for screening or ruling out of PPGLs in clinical practice. The study was published on in the January 2021 issue of the journal Clinical Biochemistry.

Related Links:
Sichuan Provincial People’s Hospital
Waters Corporation
Agilent Technologies


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.